Hội nghị công bố kết quả kinh doanh quý 3 năm 2026 của Elutia (ELUT): Hồ sơ nộp FDA cho NXT 41X đang đúng tiến độ
Doanh thu quý 3/2026 của Elutia tăng 20% lên 1,1 triệu USD trong bối cảnh công ty chuẩn bị nộp hồ sơ NXT 41X lên FDA và bổ sung thêm 26 triệu USD mà không cần chào bán cổ phần.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.